Insecticide Dermal Absorption Testing: Principles, Methods, and Regulatory Applications | ZHONGXI Testing Hong Kong, China,Global Testing and Certification Institute.

Insecticide dermal absorption testing quantifies the rate and extent to which insecticide active ingredients penetrate the skin following dermal contact, providing critical data for human health risk assessment and regulatory registration. Performed in accordance with OECD Test Guidelines 427 and 428 under GLP conditions, these studies support agrochemical dossiers, occupational exposure modeling, and product safety evaluations worldwide. Accredited third-party laboratories specializing in toxicology deliver scientifically defensible dermal absorption data for agricultural, household, and veterinary insecticide products.

Technical Overview

Dermal (percutaneous) absorption testing measures how much of an insecticide's active ingredient penetrates the skin barrier and becomes systemically available. Because skin contact is the dominant exposure route for pesticide applicators, workers re-entering treated fields, and consumers using household insect control products, dermal absorption data constitute a cornerstone of insecticide toxicology dossiers and human health risk assessments.

In a typical study, the test substance—often a radiolabeled (14C) active ingredient prepared as the commercial concentrate or the field dilution—is applied to a skin membrane mounted in a diffusion cell. Percutaneous penetration proceeds by passive diffusion through the stratum corneum and viable epidermis, a process governed by Fick's laws of diffusion and influenced by formulation type, dose level, and exposure duration. The absorbed fraction is quantified through receptor fluid kinetics, skin compartmentalization, and full mass-balance recovery. Studies are conducted under the OECD Principles of Good Laboratory Practice (GLP) and interpreted using OECD Test Guidelines 427 and 428, OECD Guidance Document No. 28, US EPA OCSPP Test Guideline 870.7600, and the EFSA Guidance on Dermal Absorption, ensuring mutual acceptance of data across regulatory jurisdictions.

Testing Samples

Agricultural Insecticide Formulations

Crop protection insecticides submitted for registration or re-evaluation, spanning all major formulation types and active ingredient classes:

Emulsifiable concentrates (EC), suspension concentrates (SC), capsule suspensions (CS), wettable powders (WP), water-dispersible granules (WG), emulsions in water (EW), ultra-low-volume (ULV) formulations, and seed-treatment products.
Pyrethroids such as lambda-cyhalothrin, deltamethrin, and cypermethrin; organophosphates such as chlorpyrifos and malathion; carbamates; neonicotinoids such as imidacloprid and thiamethoxam; avermectins such as abamectin; and diamides such as chlorantraniliprole.

Household and Public Health Insecticides

Consumer and vector-control products intended for indoor or residential use, where dermal contact is a realistic exposure scenario:

Aerosol insecticide sprays, mosquito coils, vaporizing mats, and electric liquid vaporizers.
Residual wall-surface sprays, insecticidal paints, insecticide-treated nets, baits, and gels.

Pet Care and Veterinary Insecticides

Topical spot-on products, pet sprays, flea and tick collars, and medicated shampoos, for which transdermal uptake data support both efficacy and safety assessments.

Diluted Use Solutions and Tank Mixes

The commercial concentrate and the in-use field dilution are tested in parallel, because dilution can significantly change skin partitioning and absorption behavior, and regulators require absorption values for both scenarios.

Skin Membrane Preparations

Excised human skin (dermatomed to approximately 200–500 µm) from surgical or donor sources, the preferred membrane for regulatory studies.
Pig ear skin, an accepted surrogate with permeability characteristics close to human skin.
Rat skin, used where in vitro–in vivo correlation is required.
Reconstructed human epidermis (RhE) models, suitable for screening although subject to regulatory limitations.

Testing Items

A dermal absorption study delivers a defined set of quantitative endpoints used directly in exposure and risk calculations:

Percentage of applied dose absorbed (receptor fluid plus absorbed skin fractions).
Cumulative absorbed amount versus time profile.
Steady-state flux (Jss, expressed in µg·cm⁻²·h⁻¹).
Permeability coefficient (Kp, expressed in cm·h⁻¹).
Lag time characterizing the diffusion delay through the membrane.
Distribution of the test substance among washable surface residue, stratum corneum tape strips, remaining skin, receptor fluid, and apparatus rinse.
Mass balance and total recovery, with a target recovery range of 85–115% of the applied dose.
Metabolite profiling in skin and receptor fluid where toxicologically relevant.
Final dermal absorption value derivation, for example the mean plus one standard deviation approach described in EFSA statistics for plant protection products.

Testing Methods

In Vitro Dermal Absorption (OECD TG 428)

The test formulation is applied to skin membranes mounted in static (Franz-type) or flow-through diffusion cells. The receptor fluid, typically phosphate-buffered saline supplemented with solubilizers such as bovine serum albumin, PEG 400, ethanol, or surfactants, must maintain sink conditions and membrane integrity. Skin barrier quality is verified before dosing using electrical resistance, transepidermal water loss, or tritiated water penetration. Application rates mimic realistic exposure (commonly 25 µL/cm² for liquids or 5 mg/cm² for solids), exposure typically lasts 8–10 hours followed by a soap-and-water wash, and receptor fluid is sampled at intervals up to 24 hours. Quantification is performed by liquid scintillation counting for radiolabeled materials or by validated HPLC and LC-MS/MS methods for non-labeled studies.

In Vivo Dermal Absorption (OECD TG 427)

A single dose is applied to the clipped skin of rats (or another justified species) under occluded or semi-occluded conditions for 6–10 hours, followed by collection of excreta, cage washes, blood, treated skin, and residual carcass for radioanalysis to complete a mass balance over 24 to 168 hours. Consistent with the 3Rs principles of animal welfare, in vivo studies are increasingly restricted to a supportive role, and authorities such as EFSA now base dermal absorption values primarily on in vitro data.

Skin Fractionation and Mass Balance

At study termination, the skin surface is washed to recover non-absorbed residue, and sequential tape stripping isolates the stratum corneum layers. The remaining skin is digested and analyzed separately, allowing the absorbed dose to be distinguished from material that is present in the skin but not yet systemically available. Regulatory guidance defines specific exclusion rules, such as rejecting tape-strip fractions under defined variability criteria, to derive a defensible absorption value.

Regulatory Protocol Design and Quality Assurance

Study protocols are aligned with EPA OCSPP 870.7600 and the EFSA dermal absorption guidance, requiring at least the concentrate and in-use dilution tested in parallel, non-occluded conditions to avoid exaggerated hydration, replicate membranes from a minimum of three donors, and predefined statistical treatment of variability. Analytical work is supported by validated methods, and studies are conducted under GLP with quality assurance oversight in accredited third-party laboratories.

Applications

Dermal absorption data serve multiple regulatory and commercial purposes across the insecticide lifecycle:

Active substance and formulated product registration under frameworks such as EU Regulation 1107/2009, the US FIFRA data requirements, Chinese national pesticide registration schemes aligned with GB standards, and comparable national programs.
Biocidal product authorization for household and public health insecticides under regimes such as the EU Biocidal Products Regulation.
Operator, worker, bystander, and resident exposure assessment using recognized exposure models and agricultural handler exposure databases, where the measured absorption factor is a direct input.
Replacement of conservative default absorption assumptions, which may assume up to 100% absorption, with measured values that refine margins of exposure against toxicological reference values such as the AOEL.
Derivation of personal protective equipment requirements, restricted-entry intervals, and label precautionary statements.
Safety assessment of veterinary and pet care insecticides applied directly to animal skin.
Formulation optimization and comparative safety claims, for example demonstrating that encapsulation reduces dermal penetration of a potent active ingredient.

FAQ

Question: Should a dermal absorption study follow OECD TG 427 or OECD TG 428? Answer: In vitro testing under OECD TG 428 is now the primary basis for regulatory dermal absorption values, particularly in the EU, while in vivo testing under OECD TG 427 is generally supportive. Many dossiers include an in vivo study only when in vitro–in vivo correlation is needed or when a national authority specifically requests it.

Question: Is radiolabeling of the active ingredient mandatory? Answer: No. OECD TG 428 permits validated chromatographic methods such as HPLC or LC-MS/MS for non-labeled test substances. However, radiolabeling with 14C remains the preferred approach because it simplifies full mass-balance recovery and trace-level quantification across skin and receptor compartments.

Question: Which skin source should be selected? Answer: Excised human skin is preferred and accepted by all major authorities. Pig skin is a recognized surrogate, while rat skin is used when correlation with in vivo data is required. Reconstructed human epidermis models are generally limited to screening due to their higher permeability compared with native skin.

Question: How many dose levels are tested? Answer: At minimum, the commercial concentrate and the in-use field dilution are tested in parallel, because absorption differs substantially between them. Some programs add a third dose level to characterize dose dependence or to address specific regulatory questions.

Question: What recovery is considered acceptable? Answer: Total recovery of the applied dose should fall within approximately 85–115%. Recoveries outside this range require scientific justification and may affect regulatory acceptance of the derived absorption value.

Question: How are the results used in risk assessment? Answer: The final dermal absorption percentage is inserted into exposure models to convert predicted dermal exposure into absorbed dose, which is then compared with systemic toxicological reference values to calculate margins of exposure and support registration decisions.

Question: How long does a GLP dermal absorption study take? Answer: Including protocol preparation, dose formulation, analytical method validation, the dosing phase, and reporting, studies typically require several months, so they should be scheduled early in any registration development plan.